These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 7809150)
21. Recombinant alpha-L-iduronidase: characterization of the purified enzyme and correction of mucopolysaccharidosis type I fibroblasts. Unger EG; Durrant J; Anson DS; Hopwood JJ Biochem J; 1994 Nov; 304 ( Pt 1)(Pt 1):43-9. PubMed ID: 7998955 [TBL] [Abstract][Full Text] [Related]
22. A canine model of human alpha-L-iduronidase deficiency. Spellacy E; Shull RM; Constantopoulos G; Neufeld EF Proc Natl Acad Sci U S A; 1983 Oct; 80(19):6091-5. PubMed ID: 6412235 [TBL] [Abstract][Full Text] [Related]
23. Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I. Braunlin EA; Berry JM; Whitley CB Am J Cardiol; 2006 Aug; 98(3):416-8. PubMed ID: 16860035 [TBL] [Abstract][Full Text] [Related]
29. Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice. Baldo G; Mayer FQ; Martinelli BZ; de Carvalho TG; Meyer FS; de Oliveira PG; Meurer L; Tavares A; Matte U; Giugliani R Mol Genet Metab; 2013 May; 109(1):33-40. PubMed ID: 23562162 [TBL] [Abstract][Full Text] [Related]
30. Laronidase desensitization during stem cell transplant in a child with Hurler syndrome. Rosenberg J; Jhaveri P; Kelbel T Ann Allergy Asthma Immunol; 2016 Apr; 116(4):377-8. PubMed ID: 26916445 [No Abstract] [Full Text] [Related]
31. Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. Visigalli I; Delai S; Politi LS; Di Domenico C; Cerri F; Mrak E; D'Isa R; Ungaro D; Stok M; Sanvito F; Mariani E; Staszewsky L; Godi C; Russo I; Cecere F; Del Carro U; Rubinacci A; Brambilla R; Quattrini A; Di Natale P; Ponder K; Naldini L; Biffi A Blood; 2010 Dec; 116(24):5130-9. PubMed ID: 20847202 [TBL] [Abstract][Full Text] [Related]
32. Immune response to enzyme replacement therapy: single epitope control of antigen distribution from circulation. Glaros EN; Turner CT; Parkinson EJ; Hopwood JJ; Brooks DA Mol Genet Metab; 2002; 77(1-2):127-35. PubMed ID: 12359140 [TBL] [Abstract][Full Text] [Related]
33. Enzyme replacement therapy in mucopolysaccharidosis type I. Miebach E Acta Paediatr Suppl; 2005 Mar; 94(447):58-60; discussion 57. PubMed ID: 15895714 [TBL] [Abstract][Full Text] [Related]
34. Enzyme-replacement therapy in mucopolysaccharidosis I. Kakkis ED; Muenzer J; Tiller GE; Waber L; Belmont J; Passage M; Izykowski B; Phillips J; Doroshow R; Walot I; Hoft R; Neufeld EF N Engl J Med; 2001 Jan; 344(3):182-8. PubMed ID: 11172140 [TBL] [Abstract][Full Text] [Related]
35. Pre-stem cell transplantation enzyme replacement therapy in Hurler syndrome does not lead to significant antibody formation or delayed recovery of the endogenous enzyme post-transplant: a case report. Soni S; Hente M; Breslin N; Hersh J; Whitley C; Cheerva A; Bertolone S Pediatr Transplant; 2007 Aug; 11(5):563-7. PubMed ID: 17631030 [TBL] [Abstract][Full Text] [Related]
36. A Humoral Immune Response Alters the Distribution of Enzyme Replacement Therapy in Murine Mucopolysaccharidosis Type I. Le SQ; Kan SH; Clarke D; Sanghez V; Egeland M; Vondrak KN; Doherty TM; Vera MU; Iacovino M; Cooper JD; Sands MS; Dickson PI Mol Ther Methods Clin Dev; 2018 Mar; 8():42-51. PubMed ID: 29159202 [TBL] [Abstract][Full Text] [Related]
37. Diffusion tensor imaging and myelin composition analysis reveal abnormal myelination in corpus callosum of canine mucopolysaccharidosis I. Provenzale JM; Nestrasil I; Chen S; Kan SH; Le SQ; Jens JK; Snella EM; Vondrak KN; Yee JK; Vite CH; Elashoff D; Duan L; Wang RY; Ellinwood NM; Guzman MA; Shapiro EG; Dickson PI Exp Neurol; 2015 Nov; 273():1-10. PubMed ID: 26222335 [TBL] [Abstract][Full Text] [Related]
38. Recombinant encapsulated cells overexpressing alpha-L-iduronidase correct enzyme deficiency in human mucopolysaccharidosis type I cells. Baldo G; Quoos Mayer F; Burin M; Carrillo-Farga J; Matte U; Giugliani R Cells Tissues Organs; 2012; 195(4):323-9. PubMed ID: 21778683 [TBL] [Abstract][Full Text] [Related]
39. Correction of clinical manifestations of canine mucopolysaccharidosis I with neonatal retroviral vector gene therapy. Traas AM; Wang P; Ma X; Tittiger M; Schaller L; O'donnell P; Sleeper MM; Vite C; Herati R; Aguirre GD; Haskins M; Ponder KP Mol Ther; 2007 Aug; 15(8):1423-31. PubMed ID: 17519893 [TBL] [Abstract][Full Text] [Related]
40. Retrovirus-mediated transfer of the human alpha-L-iduronidase cDNA into human hematopoietic progenitor cells leads to correction in trans of Hurler fibroblasts. Huang MM; Wong A; Yu X; Kakkis E; Kohn DB Gene Ther; 1997 Nov; 4(11):1150-9. PubMed ID: 9425437 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]